CurrentArizona Complete HealthPolicy N/A

Onychomycosis diagnostic testing (microscopy, culture, NAAT/PCR)

Criteria for outpatient diagnostic testing of fungal nail infection (onychomycosis) including microscopy/peroxidase tests, fungal culture, and culture-independent molecular tests (NAAT/PCR); intended for providers and coverage determination within the payer network.

Policy Summary

PayerArizona Complete Health

PolicyOnychomycosis diagnostic testing (microscopy, culture, NAAT/PCR)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument signs or symptoms of onychomycosis and show that test results will influence clinical management before ordering diagnostic testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3test categories

listedCPT code examples

2guideline citations

appliesMedicaid precedence

Coverage Criteria for Onychomycosis Diagnostic Testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Microscopy/Peroxidase Tests - Medically Necessary

Medically necessary when ALL of the following are met:

Microscopy/Peroxidase medical necessity: A. The member/enrollee shows signs or symptoms of onychomycosis (e.g., nails that are discolored, deformed, brittle, and/or foul-smelling; subungual debris; separation of the nail from the nail bed). B. Results of testing would influence the member/enrollee's clinical management.

Current evidence does not support microscopy/peroxidase tests for all other indications.

Fungal Culture - Medically Necessary

Medically necessary when ALL of the following are met:

Fungal culture medical necessity: A. The member/enrollee shows signs or symptoms of onychomycosis (e.g., nails that are discolored, deformed, brittle, and/or foul-smelling; subungual debris; separation of the nail from the nail bed). B. Results of testing would influence the member/enrollee's clinical management.

Current evidence does not support fungal culture for onychomycosis for all other indications.

NAAT/PCR - Not supported for all indications

Culture-independent molecular tests (NAAT/PCR):

NAAT/PCR stance: Current evidence does not support culture-independent molecular tests (NAAT/PCR) for onychomycosis for all indications.

PCR may increase detection but can detect nonpathogenic or dead fungus, which could limit its utility for identifying the true pathogen.

Culture-independent molecular tests (NAAT/PCR) can detect fungal DNA even when organisms are nonviable. As noted in guideline literature, PCR may detect nonpathogenic or dead fungus, which could limit its use in identifying the true pathogen. This limitation means a positive NAAT/PCR result does not always distinguish active infection from residual or incidental fungal material and should be interpreted in the clinical context.

Coverage of diagnostic testing is governed by the member's benefit documents and applicable plan rules. Decisions about whether a test is covered are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents; providers should confirm eligibility and any prior authorization requirements with the Health Plan before ordering testing.

This policy applies to diagnostic testing ordered for suspected onychomycosis. Microscopy/peroxidase tests, fungal culture, and NAAT/PCR are not supported when used for indications other than suspected onychomycosis or when results would not influence clinical management. Ordering these tests for unrelated indications may result in non-coverage.

Billing and Coding

Microscopy/Peroxidase TestsCPTCovered

87206	Microscopy/peroxidase test (listed as common billing codes for microscopy/peroxidase)
87220	Microscopy/peroxidase test (listed as common billing codes for microscopy/peroxidase)

Fungal CultureCPTCovered

87101	Fungal culture (listed in fungal culture group)
87102	Fungal culture (listed in fungal culture group)
87106	Fungal culture (listed in fungal culture group)
87107	Fungal culture (listed in fungal culture group)
87143	Fungal isolate identification (listed in fungal culture group)
87149	Fungal isolate identification (listed in fungal culture group)

Culture-Independent Molecular Tests (NAAT/PCR)CPT

87481	NAAT/PCR for infectious agent detection (listed for culture-independent molecular tests)
87500	NAAT/PCR (listed for culture-independent molecular tests)
87641	NAAT/PCR (listed for culture-independent molecular tests)
87652	NAAT/PCR (listed for culture-independent molecular tests)
87653	NAAT/PCR (listed for culture-independent molecular tests)
87798	NAAT/PCR (listed for culture-independent molecular tests)

Provider Actions, Documentation, and Billing

Denial Risk

Denial Risk — Unsupported Indications

Testing for onychomycosis may be denied when performed for indications that are not consistent with the medical necessity criteria or when results would not affect clinical management. Do not order microscopy, culture, or molecular testing for screening or for conditions where onychomycosis is not suspected.

Denial risk if documentation does not show signs/symptoms of onychomycosis (discolored, deformed, brittle, foul-smelling nails; subungual debris; nail separation).
Denial risk if testing is ordered for screening, cosmetic concerns, or other unsupported indications.
Denial risk if test results would not influence treatment decisions.

Documentation Required

Required Clinical Documentation

Document the clinical signs and symptoms that support a suspected diagnosis of onychomycosis and the clinical rationale for testing. Clear documentation helps demonstrate medical necessity and supports coverage.

Signs/symptoms to document: nails that are discolored, deformed, brittle, hypertrophic or hyperkeratotic; subungual debris; separation from the nail bed; nails that are foul smelling.
Clinical note must state how test results will influence management (e.g., to confirm diagnosis prior to systemic antifungal therapy or to identify organism when response to prior therapy is inadequate).
Specify the specimen site (toenail vs fingernail), prior treatments, and relevant clinical history.

Documentation Required

Documentation of Medical Necessity

Follow the Health Plan's administrative policies for demonstrating medical necessity and include supporting documentation with claims or prior authorization requests when applicable.

Provide medical records, progress notes, diagnostic rationale, and lab requisitions showing the clinical indication.
If prior authorization is required by the member's benefit plan, obtain approval before performing non-emergent testing.
Failure to supply requested documentation may result in claim denial or retrospective review.

Background and Clinical Context

Onychomycosis (tinea unguium) is a fungal infection of the nail that commonly presents with nails that are discolored, deformed, brittle, and/or foul-smelling, may have subungual debris, and can separate from the nail bed. Laboratory confirmation is recommended prior to treatment to exclude nonfungal conditions, detect mixed infections, and identify forms that may respond differently to therapy. Traditional methods include microscopy and culture; molecular NAAT/PCR tests can increase detection but have the limitation of potentially detecting nonviable or nonpathogenic organisms, which can complicate interpretation.

Definitions

inv-19: Onychomycosis (tinea unguium) — definition and key features

DefinitionOnychomycosis (tinea unguium): fungal infection of the nails characterized by discoloration, deformity, subungual debris, brittleness, and possible separation from the nail bed; may affect surrounding skin.

Common signs/symptomsNails that are discolored, deformed, brittle, hypertrophic or hyperkeratotic, may have subungual debris, separation from the nail bed, or foul smell.

When testing is indicatedMicroscopy/peroxidase testing or fungal culture is considered medically necessary when the member shows signs/symptoms of onychomycosis and test results would influence clinical management.

Limitations of NAAT/PCRPCR may increase detection but can detect nonpathogenic or dead fungus, which can limit its utility for identifying the true pathogen; current evidence does not support NAAT/PCR for all indications.

inv-20: Health Plan — definition/usage in this policy

DefinitionHealth Plan: a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

Policy purposeThis clinical policy provides guidance on medical necessity to assist coverage decisions and benefit administration; it is not a contract or guarantee of payment.

Provider responsibilityProviders must exercise professional medical judgment; the policy does not dictate medical care and providers remain responsible for treatment decisions.

Coverage determinationsCoverage decisions are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents and applicable state/federal requirements; providers should obtain prior authorization per plan procedures as required.